2012
Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome
Lazova R, Camp RL, Klump V, Siddiqui SF, Amaravadi RK, Pawelek JM. Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome. Clinical Cancer Research 2012, 18: 370-379. PMID: 22080440, PMCID: PMC4825867, DOI: 10.1158/1078-0432.ccr-11-1282.Peer-Reviewed Original ResearchConceptsMelanoma tissue microarrayTissue microarrayBreast cancerLC3B expressionClinical outcomesNuclear gradeKi-67Solid tumorsHigh LC3B expressionHigh nuclear gradeMultitumor tissue microarrayTypes of cancerHigh LC3BCutaneous metastasesPoor outcomeWorse outcomesHistopathologic gradingLC3B stainingTherapeutic vulnerabilitiesTumorsCancerCancer progressionMetastasisMitotic figuresLC3B levelsQuantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer
Agarwal S, Gertler FB, Balsamo M, Condeelis JS, Camp RL, Xue X, Lin J, Rohan TE, Rimm DL. Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer. Breast Cancer Research 2012, 14: r124. PMID: 22971274, PMCID: PMC3962029, DOI: 10.1186/bcr3318.Peer-Reviewed Original ResearchConceptsBreast cancer cohortBreast cancerPoor outcomeTumor cellsCancer cohortPoor disease-specific survivalDisease-specific deathDisease-specific survivalBreast cancer patientsIndependent prognostic markerIndependent breast cancer cohortsNon-invasive tumor cellsInvasive tumor cellsReceptor statusNode statusTumor sizeCancer patientsPrognostic markerSignificant associationCohortCancerIsoform expressionPatientsMetastasisOutcomes
2011
Lymph Node Ratio Should Be Considered for Incorporation into Staging for Breast Cancer
Chagpar AB, Camp RL, Rimm DL. Lymph Node Ratio Should Be Considered for Incorporation into Staging for Breast Cancer. Annals Of Surgical Oncology 2011, 18: 3143. PMID: 21847696, DOI: 10.1245/s10434-011-2012-9.Peer-Reviewed Original ResearchConceptsNode-positive breast cancer patientsDifferent OS ratesOverall survivalBreast cancer patientsOS independentClinicopathologic factorsOS ratesCancer patientsBreast cancer staging systemCurrent American Joint CommitteeLymph node ratioAdditional prognostic informationAmerican Joint CommitteeCancer (AJCC) staging systemTraditional clinicopathologic factorsPN statusIntermediate riskNodal statusStaging systemPrognostic informationBreast cancerHigh riskLower riskJoint CommitteeNode ratio
2010
Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models
Parisi F, González A, Nadler Y, Camp RL, Rimm DL, Kluger HM, Kluger Y. Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Research 2010, 12: r66. PMID: 20809974, PMCID: PMC3096952, DOI: 10.1186/bcr2633.Peer-Reviewed Original ResearchConceptsNottingham Prognostic IndexClinico-pathological variablesPrognostic indexCox modelPrognostic modelMultivariate Cox regression modelEarly-stage breast cancerBreast cancer patient cohortsAdjuvant chemotherapy decisionsMultivariate Cox modelStage breast cancerCox regression modelCancer patient cohortsTime-dependent areaBreast cancer prognostic modelsCancer prognostic modelsNPI groupOncotype DXPatient cohortChemotherapy decisionsPrognostic markerBackward selection procedureBreast cancerQuantitative immunofluorescence methodImmunofluorescence methodPMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer
VanHouten J, Sullivan C, Bazinet C, Ryoo T, Camp R, Rimm DL, Chung G, Wysolmerski J. PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2010, 107: 11405-11410. PMID: 20534448, PMCID: PMC2895115, DOI: 10.1073/pnas.0911186107.Peer-Reviewed Original ResearchConceptsPMCA2 expressionBreast cancerT47D breast cancer cellsIntracellular calcium levelsBreast cancer progressionBreast cancer cellsEpithelial cell apoptosisPoor outcomeIntracellular calciumCalcium levelsMammary gland involutionCancer progressionCell apoptosisCancer cellsMammary involutionApoptosisGland involutionCancerMammary epithelial cell apoptosisOutcomesPMCA2Triggers apoptosisApical surfaceExpressionOverexpressionIn Situ Identification of Putative Cancer Stem Cells by Multiplexing ALDH1, CD44, and Cytokeratin Identifies Breast Cancer Patients with Poor Prognosis
Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL. In Situ Identification of Putative Cancer Stem Cells by Multiplexing ALDH1, CD44, and Cytokeratin Identifies Breast Cancer Patients with Poor Prognosis. American Journal Of Pathology 2010, 176: 2131-2138. PMID: 20228222, PMCID: PMC2861079, DOI: 10.2353/ajpath.2010.090712.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAldehyde DehydrogenaseAldehyde Dehydrogenase 1 FamilyBreast NeoplasmsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansHyaluronan ReceptorsIsoenzymesKeratinsMiddle AgedNeoplastic Stem CellsPrognosisRetinal DehydrogenaseRetrospective StudiesConceptsCancer stem cellsPutative cancer stem cellsBreast cancerIdentifies high-risk patientsPresence of CSCsNode-positive patientsHigh-risk patientsBreast cancer patientsAggressive tumor behaviorParaffin-embedded breast cancer tissuesBreast cancer tissuesFlow cytometric studyStem cellsMean followNodal statusRisk patientsTumor persistenceCD44 positivityPoor prognosisPrognostic valueTumor sizeHistological gradeALDH1 positivityCancer patientsWorse outcomes
2009
Molecular Classification of Normal and Cancer Mammospheres.
Agarwal S, Camp R, Lannin D, Halligan K, Stern D, Tuck D, Harris L, Rimm D. Molecular Classification of Normal and Cancer Mammospheres. Cancer Research 2009, 69: 501-501. DOI: 10.1158/0008-5472.sabcs-09-501.Peer-Reviewed Original ResearchCancer stem cellsPrimary tumorBreast cancerTumor cellsStem cellsAbsence of CD24Breast cancer specimensHuman breast cancerFine-needle aspirationNormal breast tissueExpression of CD44Tumor tissue samplesPutative stem cell markersCD44-positive cellsKey protein markersEx vivo cultureStem cell markersNovel drug targetsSpecific therapyTreatment successNeedle aspirationCancer specimensMyoepithelial markersBT-20Positive cellsGrowth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer
Nadler Y, González AM, Camp RL, Rimm DL, Kluger HM, Kluger Y. Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. Annals Of Oncology 2009, 21: 466-473. PMID: 19717535, PMCID: PMC2826097, DOI: 10.1093/annonc/mdp346.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBlotting, WesternBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularFemaleFluorescent Antibody TechniqueFollow-Up StudiesGRB7 Adaptor ProteinHumansImage Processing, Computer-AssistedMiddle AgedPrognosisReceptor, ErbB-2Survival RateTissue Array AnalysisTumor Cells, CulturedYoung AdultConceptsHER2/neuBreast cancerPrognostic markerHER2/neu-positive breast cancerGRB7 expressionHigh HER2/neuNeu-positive breast cancerHER2/neu overexpressionPrimary breast cancerBreast cancer patientsIndependent prognostic markerNode-positive subsetValuable prognostic markerProtein 7Cy5-conjugated antibodiesMultivariable analysisWorse prognosisEntire cohortCancer patientsNeu overexpressionTissue microarrayTherapeutic targetCancerNeuPatientsIn situ characterization of possible cancer stem cells in breast cancer by multiplexing ALDH1, CD44 and cytokeratin on tissue microarrays.
Neumeister V, Agarwal S, Camp R, Rimm D. In situ characterization of possible cancer stem cells in breast cancer by multiplexing ALDH1, CD44 and cytokeratin on tissue microarrays. Cancer Research 2009, 69: 102. DOI: 10.1158/0008-5472.sabcs-102.Peer-Reviewed Original Research
2008
Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancer
Sullivan CA, Ghosh S, Ocal IT, Camp RL, Rimm DL, Chung GG. Microvessel area using automated image analysis is reproducible and is associated with prognosis in breast cancer. Human Pathology 2008, 40: 156-165. PMID: 18799189, DOI: 10.1016/j.humpath.2008.07.005.Peer-Reviewed Original ResearchConceptsVIII-related antigenMicrovessel densityMicrovessel areaBreast cancerFactor VIII-related antigenPrimary breast cancerEstrogen receptor negativityReceptor negativityNode positivityClinical outcomesEvaluable casesPrognostic parametersAngiogenic biomarkersLarge tumorsYear survivalQuantitative image analysis systemTissue microarrayTumorsCD31Multivariate levelVessel compartmentPoor associationCancerAntigenCD34High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer
Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL, Chung GG. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Human Pathology 2008, 39: 1835-1843. PMID: 18715621, PMCID: PMC2632946, DOI: 10.1016/j.humpath.2008.06.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularConnecticutFemaleFluorescent Antibody Technique, IndirectHumansImage Processing, Computer-AssistedImmunoenzyme TechniquesKaplan-Meier EstimateMiddle AgedNeuropilin-1Receptors, Vascular Endothelial Growth FactorSurvival RateTissue Array AnalysisVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2Young AdultConceptsVascular endothelial growth factorEndothelial growth factorBreast cancerVEGFR-1Growth factorNeuropilin-1VEGFR-2Kaplan-Meier survival analysisBreast cancer tissue microarrayVascular endothelial growth factor receptorPrimary breast cancerStandard prognostic factorsEndothelial growth factor receptorPrimary breast adenocarcinomaCancer tissue microarrayTumor-specific expressionGrowth factor receptorPrognostic factorsPrognostic significancePrognostic valueWorse outcomesLarge cohortTissue microarraySurvival analysisSignificant associationExpression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer
Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y. Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer. Clinical Cancer Research 2008, 14: 4455-4462. PMID: 18628459, PMCID: PMC5849429, DOI: 10.1158/1078-0432.ccr-07-5268.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAurora Kinase BAurora KinasesBiomarkers, TumorBlotting, WesternBreast NeoplasmsCell Line, TumorFemaleHistory, 17th CenturyHumansImage Processing, Computer-AssistedImmunohistochemistryKaplan-Meier EstimatePrognosisProtein Serine-Threonine KinasesTissue Array AnalysisConceptsBreast cancerB expressionAurora B expressionBreast tumorsHigh AuroraEarly-stage breast cancerHER-2/neuProgesterone receptor expressionSubset of patientsPopulation of patientsIndependent prognostic markerHigh nuclear gradePrimary breast tumorsCy5-conjugated antibodiesPathologic variablesPrognostic roleMultivariable analysisProspective studyNuclear gradePrognostic markerReceptor expressionClinical developmentPatientsPredictive roleCancerEstrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome
Harigopal M, Heymann J, Ghosh S, Anagnostou V, Camp RL, Rimm DL. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome. Breast Cancer Research And Treatment 2008, 115: 77-85. PMID: 18521745, DOI: 10.1007/s10549-008-0063-9.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAutomationBiomarkers, TumorBreast NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansMultivariate AnalysisNuclear Receptor Coactivator 3Oligonucleotide Array Sequence AnalysisPrognosisProportional Hazards ModelsReceptors, EstrogenReceptors, ProgesteroneRegression AnalysisTranscription FactorsTreatment OutcomeConceptsHigh AIB1 expressionTranscription intermediary factor 2Poor patient outcomesAIB1 expressionTissue microarrayPatient outcomesHER2/neu statusBreast cancer tissue microarrayFluorescent immunohistochemical stainingWorse overall survivalUnivariate survival analysisBreast cancer specimensCancer tissue microarrayHER2/neuCoregulatory proteinsCox univariate survival analysesBreast tissue microarraysOverall survivalER statusPR statusPrognostic significanceIndependent associationBreast cancerPrognostic biomarkerImmunohistochemical stainingExpression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer
Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Research 2008, 10: r35. PMID: 18430249, PMCID: PMC2397537, DOI: 10.1186/bcr1998.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsDNA-Binding ProteinsDrug Resistance, NeoplasmFemaleFluorescent Antibody TechniqueFollow-Up StudiesGene Expression Regulation, NeoplasticHumansImmunohistochemistryKaplan-Meier EstimateLymphatic MetastasisMiddle AgedPredictive Value of TestsPrognosisProportional Hazards ModelsProtein Array AnalysisProto-Oncogene Proteins c-bcl-2Receptors, EstrogenReceptors, ProgesteroneTranscription FactorsTreatment OutcomeConceptsNode-positive subsetHER2/neuProgesterone receptorBreast cancerEstrogen receptorBcl-2 expressionBAG-1 expressionImproved survivalBcl-2Anti-apoptotic mediator Bcl-2Breast tumorsSteroid receptor positivitySubset of patientsBAG-1Antihormonal therapyFavorable prognosisReceptor positivityMultivariable analysisPathological variablesEntire cohortPrognostic valuePrognostic markerImproved outcomesLarge cohortClinical development
2007
High HSP90 Expression Is Associated with Decreased Survival in Breast Cancer
Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM. High HSP90 Expression Is Associated with Decreased Survival in Breast Cancer. Cancer Research 2007, 67: 2932-2937. PMID: 17409397, DOI: 10.1158/0008-5472.can-06-4511.Peer-Reviewed Original ResearchConceptsHigh HSP90 expressionBreast cancerHER2/neuHSP90 expressionEstrogen receptorHigh HER2/neuCell linesEarly-stage breast cancerHER2/neu expressionHuman tumorsLymph node involvementPrimary breast cancerSubset of patientsPopulation of patientsIndependent prognostic markerHigh nuclear gradeBreast cancer cell linesBreast cancer progressionCy5-conjugated antibodiesCancer cell linesNode involvementPathologic variablesPrognostic roleMultivariable analysisProspective studyAntibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model
Pozner-Moulis S, Cregger M, Camp RL, Rimm DL. Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Laboratory Investigation 2007, 87: 251-260. PMID: 17260003, DOI: 10.1038/labinvest.3700515.Peer-Reviewed Original ResearchConceptsExpression of METPrognostic valueBreast cancerProtein expressionShorter disease-specific survivalDisease-specific survivalInvasive breast cancerHepatocyte growth factor receptorGrowth factor receptorNeck carcinomaAssessment of reproducibilityIntracellular domainTissue microarrayPotential biomarkersCell line controlAntibody validationNuclear MetCancerFactor receptorAntibodiesMetSMet receptorVariable resultsReceptorsCompartmental analysisQuantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome
Zerkowski MP, Camp RL, Burtness BA, Rimm DL, Chung GG. Quantitative Analysis of Breast Cancer Tissue Microarrays Shows High Cox-2 Expression Is Associated with Poor Outcome. Cancer Investigation 2007, 25: 19-26. PMID: 17364553, DOI: 10.1080/07357900601128825.Peer-Reviewed Original ResearchConceptsCOX-2 expressionCOX-2Tissue microarrayBreast cancerEstrogen receptorPrognostic factorsWorse survivalProgesterone receptorX-tileOptimal cutpointHigh COX-2 expressionBreast cancer tissue microarrayX-tile analysisSignificant prognostic factorsPrimary breast cancerCOX-2 inhibitorsCancer tissue microarrayHER2/neuClinicopathologic factorsNodal statusPoor outcomePoor prognosisTumor sizePredictive biomarkersClinical trials
2006
Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays
Dolled-Filhart M, Rydén L, Cregger M, Jirström K, Harigopal M, Camp RL, Rimm DL. Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays. Clinical Cancer Research 2006, 12: 6459-6468. PMID: 17085660, DOI: 10.1158/1078-0432.ccr-06-1383.Peer-Reviewed Original ResearchConceptsBreast cancerPatient outcomesTissue microarraySubset of patientsBreast cancer patientsTissue microarray platformInternal validation setRoutine pathology laboratoriesCancer patientsEstrogen receptorTissue biomarkersIndependent cohortTumor subtypesPredictive valueAcid-base analysisPathology laboratoryRNA expression studiesCancerTissue sectionsPatientsCohortOutcomesFurther validationObjective quantitative analysisBiomarker discoveryQuantitative In situ Analysis of β-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor Outcome
Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL, Rimm DL. Quantitative In situ Analysis of β-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor Outcome. Cancer Research 2006, 66: 5487-5494. PMID: 16707478, DOI: 10.1158/0008-5472.can-06-0100.Peer-Reviewed Original ResearchConceptsProgesterone receptorEstrogen receptorPrognostic valueBreast cancerKi-67X-tile softwareProportional hazards modelBreast cancer prognosisBreast cancer showBreast cancer tumorsΒ-catenin expressionYale Pathology archivesHazard ratioNode statusPoor outcomeTumor sizePrognostic markerWorse outcomesImmunohistochemical studyNuclear gradeCase cohortLow-level expressionPathology archivesTissue microarrayBeta-catenin expression
2005
Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer
McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer. Clinical Cancer Research 2005, 11: 5188-5194. PMID: 16033835, DOI: 10.1158/1078-0432.ccr-05-0158.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBreast NeoplasmsCase-Control StudiesFemaleFollow-Up StudiesGene Expression ProfilingHumansMiddle AgedMultivariate AnalysisOligonucleotide Array Sequence AnalysisPrognosisReceptors, TNF-Related Apoptosis-Inducing LigandReceptors, Tumor Necrosis FactorSurvival AnalysisConceptsEarly-stage breast cancerTRAIL-R2 expressionBreast cancerPrognostic valueTRAIL-R2TRAIL-R1Normal breast specimensTumor necrosis factor-related apoptosis-inducing ligand receptor 1Lymph node involvementSubset of patientsBreast cancer patientsIndependent prognostic markerTRAIL-R1 expressionNormal breast epitheliumTRAIL receptor expressionLigand receptor 1Apoptosis-inducing ligand receptor 1Adjuvant treatmentNode involvementNodal statusPathologic variablesTumor sizeCancer patientsClinical trialsPrognostic marker